introduct
neonat
less
respons
vaccin
adult
make
harder
protect
newborn
infect
neonat
differ
antigenpres
cell
b
cell
function
like
contribut
key
question
whether
novel
adjuv
might
abl
make
neonat
vaccin
effect
area
cover
review
address
issu
improv
neonat
vaccin
defin
vaccin
given
first
week
life
human
infant
first
week
life
mous
search
perform
use
keyword
includ
neonat
immun
neonat
immunis
vaccin
adjuv
pubm
articl
publish
expert
opinion
sugarlik
structur
recent
shown
prime
infant
adapt
immun
system
respond
vaccin
potenti
effect
tradit
adjuv
sugarbas
compound
benefici
adjuv
effect
neonat
vaccin
model
includ
delta
inulin
advax
curdlan
trehalos
compound
make
interest
neonat
adjuv
candid
either
use
alon
combin
tradit
innat
immun
adjuv
articl
histori
accord
world
health
organ
million
death
annual
occur
first
week
neonat
life
fiftytwo
percent
million
children
die
year
age
die
infecti
caus
virus
bacteria
parasit
contribut
infant
morbid
mortal
influenza
respiratori
syncyti
viru
rsv
common
caus
acut
lower
respiratori
infect
alri
children
influenza
annual
global
attack
rate
children
versu
adult
children
age
year
greater
rate
hospit
complic
particularli
presenc
coexist
ill
cohort
us
infant
monitor
weekli
birth
year
age
develop
influenza
infect
retrospect
cohort
studi
children
hospit
communityacquir
influenza
four
consecut
influenza
season
juli
june
month
old
children
year
old
alon
estim
children
die
worldwid
result
influenzaassoci
alri
annual
global
burden
rsvassoci
alri
estim
million
case
result
million
hospit
death
year
age
rsv
children
year
age
account
time
death
influenza
around
children
develop
rsvspecif
antibodi
month
age
year
virtual
children
expos
newborn
immun
system
tradit
view
immatur
medawar
colleagu
propos
immatur
newborn
immun
system
function
barrier
autoimmun
although
matur
b
cell
detect
fetal
liver
week
gestat
newborn
immun
system
exhibit
reduc
respons
activ
immun
neonat
respond
immun
qualit
quantit
lower
memori
immun
respons
recent
suggest
reduc
neonat
immun
defect
state
immatur
rather
reflect
necessari
adapt
immun
system
demand
place
earli
life
regardless
problem
remain
vaccin
neonat
period
result
lower
antibodi
cell
respons
compar
adult
result
reduc
abil
use
vaccin
prevent
neonat
morbid
mortal
infect
success
neonat
vaccin
requir
develop
strategi
overcom
reduc
adapt
immun
respons
infanc
tradit
inflammatori
adjuv
improv
adult
vaccin
respons
less
success
neonat
adjuv
act
varieti
way
increas
recruit
immun
cell
site
inject
enhanc
migrat
activ
apc
drain
lymph
node
increas
uptak
ag
apc
increas
apc
antigen
present
costimul
result
enhanc
adapt
immun
respons
review
adult
manifest
higher
frequenc
helper
cell
higher
antibodi
ab
titer
key
question
whether
benefit
adjuv
util
creat
effect
neonat
vaccin
review
explor
problem
neonat
immun
identifi
potenti
adjuv
solut
focuss
new
find
respect
uniqu
benefit
sugarbas
adjuv
compound
low
andor
delay
respons
mani
vaccin
seen
neonat
anim
model
reflect
seen
human
newborn
neonat
reduc
vaccin
respons
differ
innat
adapt
immun
pathway
compar
adult
furthermor
passiv
acquir
matern
ab
help
protect
neonat
earlylif
infect
may
also
contribut
inhibit
neonat
vaccin
respons
antigen
interfer
featur
neonat
immun
system
illustr
figur
immun
system
earlylif
skew
toward
immun
toler
need
avoid
autoimmun
inflammatori
immunopatholog
reflect
increas
activ
suppress
regulatori
cell
reduc
antigenpres
cell
apc
function
higher
threshold
b
cell
activ
reduc
product
immun
effector
inflammatori
cytokin
bia
helper
type
phenotyp
apc
includ
dendrit
cell
dc
macrophag
monocyt
express
rang
receptorsmolecul
respond
pathogenassoci
molecular
pattern
pamp
damageassoci
molecular
pattern
damp
four
major
class
receptor
includ
tolllik
receptor
tlr
nodlik
receptor
nlr
retino
acidinduc
gene
rigi
like
receptor
rlr
ctype
lectin
receptor
clr
activ
receptor
result
innat
immun
stimul
increas
proinflammatori
cytokin
product
upregul
costimulatori
molecul
mhcii
facilit
increas
ag
present
memori
b
cell
neonat
apc
express
low
basal
level
costimulatori
molecul
mhcii
decreas
abil
produc
cytokin
particularli
respons
tlr
stimul
downstream
effect
reduc
activ
expans
memori
b
cell
inflammatori
adjuv
base
pamp
damp
enhanc
apc
function
effect
adult
whole
poorli
effect
neonat
suggest
develop
effect
neonat
adjuv
requir
fresh
approach
simpli
reli
repurpos
adjuv
shown
work
adult
follicular
dc
fdc
play
essenti
role
b
cell
respons
captureretain
ag
form
immun
complex
extend
period
therebi
draw
togeth
agspecif
b
cell
fdc
develop
slowli
birth
result
delay
germin
center
gc
format
abil
produc
high
affin
ab
ab
current
defin
correl
protect
major
success
vaccin
infecti
agent
even
vaccin
induc
ab
respons
neonat
induc
ab
quantit
lower
qualit
inferior
compar
older
individu
lower
neonat
ab
respons
reflect
limit
gc
extrafollicular
plasma
cell
respons
low
apc
ag
express
combin
low
express
costimulatori
molecul
caus
reduc
b
cell
receptor
bcr
signal
henc
less
ab
avid
matur
isotyp
switch
neonat
slow
matur
margin
zone
neonat
b
cell
subset
pamprespons
b
cell
mount
rapid
tindepend
extra
follicular
b
cell
respons
extrins
factor
influenc
magnitud
persist
qualiti
neonat
vaccin
respons
also
includ
matern
deriv
ab
increas
frequenc
regulatori
cell
treg
matern
ab
reduc
neonat
vaccin
respons
also
effect
matern
deriv
antibodi
may
mask
key
epitop
vaccin
therefor
success
vaccin
formul
abl
circumv
overcom
function
peculiar
neonat
period
abbrevi
apc
antigenpres
cell
ref
mask
neutral
ab
epitop
bind
dispos
antigen
neutral
attenu
vaccin
vector
treg
present
higher
level
birth
administr
bcg
hbv
vaccin
mice
togeth
ab
treatment
deplet
treg
result
higher
vaccin
respons
human
infant
malaria
infect
associ
increas
malariaspecif
treg
correl
decreas
respons
bcg
vaccin
persist
year
age
henc
adjuv
reduc
treg
could
benefici
neonat
vaccin
problem
tradit
pampbas
adjuv
tlr
agonist
typic
stimul
treg
antiinflammatori
cytokin
neonat
therebi
hinder
rather
help
neonat
vaccin
respons
lymphocyt
main
adapt
immun
cell
respons
bcell
help
cytotox
kill
infect
cell
respect
respons
vaccin
acut
infect
agspecif
cell
prolifer
differenti
differ
th
subset
eg
follicular
helper
tfh
cell
character
differ
cytokin
profil
mediat
function
diminish
cell
respons
predispos
neonat
infect
intracellular
pathogen
impair
tcell
function
earli
life
attribut
low
cell
precursor
frequenc
plu
reduc
quantiti
qualiti
apc
domin
antiinflammatori
cytokin
milieu
preferenti
support
develop
rather
respons
moreov
shown
mice
express
heteromer
receptor
neonat
cell
render
suscept
apoptosi
upon
bind
nevertheless
reduc
capac
neonat
absolut
develop
respons
infect
vaccin
eg
bcg
pertussi
cytomegaloviru
infect
memori
tcell
subtyp
critic
vaccin
affect
type
qualiti
bcell
respons
mice
cytokin
induc
class
switch
iga
wherea
cytokin
primarili
induc
igm
iga
ige
antibodi
tfh
cell
essenti
gener
highaffin
memori
b
cell
gc
reaction
produc
plu
induc
ab
product
respect
also
tfh
cell
play
import
role
promot
iga
product
home
igacommit
b
cell
mucos
site
tfh
cell
tonsil
peyer
patch
produc
synerg
transform
growth
factor
skew
isotyp
switch
toward
iga
also
downregul
chemokin
receptor
promot
follicular
local
b
cell
upregul
chemokin
receptor
facilit
migrat
iga
classswitch
b
cell
local
mucos
effector
site
limit
neonat
gc
b
cell
plasma
cell
respons
correl
delay
matur
fdc
reduc
expans
tfh
cell
tfh
cell
like
limit
humor
respons
vaccin
earli
life
adjuv
support
neonat
tfh
cell
differenti
could
benefici
improv
neonat
vaccin
respons
given
difficulti
neonat
vaccin
much
could
learn
vaccin
prove
success
neonat
period
bcg
hbv
vaccin
routin
administ
neonat
part
expand
program
immun
epi
schedul
gain
insight
vaccin
induc
neonat
protect
may
help
develop
strategi
induc
protect
neonat
respons
vaccin
bcg
live
attenu
mycobacterium
bovi
vaccin
administ
singl
dose
within
first
day
life
develop
countri
prevent
tubercul
mening
dissemin
tb
children
bcg
contain
inher
adjuv
activ
express
factor
stimul
pamp
receptor
includ
mincl
effect
bcg
link
abil
induc
strong
neonat
immun
respons
due
activ
pamp
receptor
indic
right
immun
signal
induc
favor
adapt
immun
respons
earli
life
nevertheless
poor
bcg
efficaci
region
closer
equat
associ
prior
treg
induct
environment
mycobacteria
highlight
challeng
even
success
neonat
vaccinelik
bcg
hbv
vaccin
formul
aluminum
salt
adjuv
hydroxid
phosphat
immun
administ
birth
reduc
risk
mothertoinf
transmiss
hbv
children
routin
receiv
three
dose
hbv
vaccin
part
childhood
immun
schedul
first
dose
administ
within
h
birth
second
third
dose
administ
month
month
age
respect
strategi
highli
effect
prevent
acut
chronic
hbv
infect
infant
born
mother
hbv
posit
notabl
dynam
prevent
infect
time
birth
birth
dose
hbv
vaccin
differ
use
birth
dose
vaccin
protect
prospect
infect
influenza
rsv
short
durat
lowlevel
immun
induc
birth
dose
may
suffici
protect
week
vaccin
administr
also
recommend
oral
polio
vaccin
opv
dose
birth
follow
seri
three
opv
dose
polioendem
countri
half
newborn
receiv
monovalentopv
seroconvert
day
prime
show
strategi
effect
howev
opv
live
infecti
vaccin
also
contain
rna
therebi
ensur
abil
activ
damp
pamp
effect
act
inbuilt
adjuv
like
explain
effect
neonat
oppos
vaccin
mention
vaccin
administ
neonat
phase
pass
start
month
age
vaccin
administ
infant
includ
rotaviru
vaccin
month
diphtheria
pertussi
tetanu
dtap
month
hib
conjug
month
pneumococc
conjug
pcv
month
ipv
month
season
influenza
month
older
measl
mump
rubella
mmr
month
varicella
month
hepat
month
review
major
reason
delay
twofold
first
agedepend
increas
seroconvers
rate
vaccin
delay
also
delay
avoid
much
potenti
problem
matern
antibodi
interfer
mani
attempt
immun
children
birth
vaccin
unsuccess
exampl
immun
birth
pertussi
vaccin
result
reduc
respons
pertussi
booster
month
age
independ
matern
ab
convers
immun
delay
week
age
serolog
respons
pertussi
significantli
improv
studi
rotaviru
vaccin
similarli
found
respons
less
robust
earlier
life
vaccin
given
question
also
rais
whether
neonat
vaccin
might
induc
persist
immun
hyporespons
due
immun
paralysi
toler
ag
interfer
exampl
dtap
vaccin
given
birth
associ
significantli
reduc
ab
respons
dtap
booster
month
age
summari
two
three
vaccin
given
birth
live
organ
bcg
rotaviru
express
multipl
inbuilt
pamp
act
infect
also
induc
endogen
damp
therebi
explain
effect
third
exampl
recombin
antigen
hbsag
role
birth
dose
vaccin
protect
immedi
infect
transmiss
time
birth
subsequ
immun
provid
addit
immun
start
month
key
question
whether
specif
adjuv
adjuv
combin
could
use
replic
effect
live
bcg
rotaviru
vaccin
therebi
improv
neonat
vaccin
respons
alri
common
caus
infant
mortal
worldwid
influenza
rsv
parainfluenza
human
metapneumoviru
common
caus
alri
children
vaccin
primari
strategi
prevent
influenza
current
licens
influenza
vaccin
includ
trival
quadrival
inactiv
vaccin
tivqiv
intranas
live
attenu
influenza
vaccin
laiv
even
though
tivqiv
laiv
effect
prevent
influenza
associ
complic
children
month
older
neither
indic
neonat
due
poor
respons
inactiv
vaccin
increas
side
effect
laiv
vaccin
singl
dose
tiv
fail
induc
seroconvers
strain
infant
less
month
age
seroprotect
seen
infant
even
second
dose
correl
age
first
immun
rate
seroconvers
leav
neonat
highli
vulner
infect
absenc
effect
neonat
influenza
vaccin
vaccin
licens
anywher
world
prevent
rsv
diseas
initi
rsv
vaccin
test
formalininactiv
wholeviru
vaccin
formul
alum
adjuv
although
infant
immun
seri
administ
month
age
develop
rsvspecif
serum
ab
respons
nonneutr
fail
protect
rsv
infect
ultim
exacerb
infect
outcom
vaccineenhanc
diseas
major
obstacl
remain
success
develop
neonat
rsv
vaccin
although
high
serum
neutral
ab
titer
abl
prevent
alri
due
rsv
adult
difficult
induc
high
ab
level
neonat
even
adjuv
could
induc
high
ab
respons
neonat
still
issu
vaccineenhanc
diseas
data
rodent
model
suggest
vaccineenhanc
diseas
associ
prime
excess
respons
factor
exacerb
adjuv
alum
although
altern
adjuv
notabl
tlr
agonist
suggest
overcom
problem
rsv
vaccineenhanc
diseas
anim
model
even
tlr
agonist
bia
young
infant
abil
use
strategi
prevent
vaccineenhanc
diseas
yet
confirm
human
infant
novel
adjuv
may
assist
develop
effect
neonat
vaccin
current
major
focu
tlr
agonist
ligand
primarili
enhanc
ab
product
wherea
ligand
promot
polar
respons
review
monophosphoryl
lipid
mpla
ligand
combin
alum
enhanc
ab
respons
howev
tlr
adjuv
demonstr
effect
older
children
adult
still
guarante
work
human
neonat
neonat
exhibit
reduc
respons
tlr
inflammasom
pathway
particular
defect
procaspas
cleavag
contribut
low
respons
human
neonat
cell
adjuv
target
pathway
endosom
tlr
may
better
preserv
activ
neonat
experi
still
abl
fulli
compens
reduc
respons
influenza
vaccin
neonat
mice
manuscript
prepar
depict
figur
addit
adjuv
neonat
vaccin
formul
might
help
acceler
matur
neonat
immun
system
therebi
enhanc
ag
present
increas
b
cell
costimulatori
signal
overrid
reduc
neonat
vaccin
respons
adjuv
could
potenti
use
enhanc
neonat
tfh
cell
respons
increas
frequenc
qualiti
gc
memori
b
cell
respons
therebi
enhanc
highaffin
broadli
neutral
ab
product
addit
enhanc
cellular
immun
unfortun
pauciti
avail
data
util
adjuv
enhanc
immun
respons
vaccin
human
neonat
alum
adjuv
hbv
vaccin
effect
infant
adult
effect
preterm
neonat
neonat
data
novel
adjuv
still
come
neonat
anim
model
uncertainti
well
might
reflect
situat
human
neonat
squalen
oil
emuls
adjuv
fail
induc
protect
influenza
antibodi
respons
use
immun
old
mice
vaccin
even
second
booster
dose
administ
contrast
lipid
agonist
report
enhanc
b
cell
respons
polysaccharid
pneumococc
vaccin
administ
rhesu
macaqu
first
day
life
overal
pauciti
data
demonstr
tradit
adjuv
use
adult
effect
neonat
note
previous
bcg
one
vaccin
effect
newborn
bcg
express
glycolipid
glycopeptid
sugarbas
structur
potent
activ
innat
immun
system
success
bcg
rais
question
whether
sugarbas
immun
activ
may
abl
preferenti
activ
neonat
immun
system
trehalos
tdb
synthet
analog
mycobacteriallyexpress
tdm
target
pamp
receptor
mincl
macrophag
induc
ca
depend
lectin
receptor
tdb
shown
activ
human
newborn
dc
enhanc
polar
cytokin
product
dc
given
combin
tdb
enhanc
protect
influenza
immun
neonat
mice
induct
tfh
cell
highaffin
plasma
cell
cation
adjuv
formul
consist
tdb
dimethyl
dioctadecyl
ammonium
dda
deliveri
vehicl
success
induc
respons
murin
neonat
curdlan
waterinsolubl
linear
produc
bacteria
also
shown
enhanc
respons
subunit
tb
vaccin
influenza
vaccin
neonat
mice
zymosan
glucosebas
polysaccharid
express
yeast
activ
multipl
pamp
receptor
includ
glucan
receptor
induc
compar
cytokin
level
cord
blood
adult
blood
monocyt
dc
rais
possibl
may
also
effect
neonat
adjuv
data
support
hypothesi
sugarbas
compound
may
uniqu
activ
neonat
adapt
immun
system
way
support
induct
adultlik
memori
respons
although
exact
mechan
favor
action
known
tdb
known
activ
mincl
curdlan
activ
mincl
ctype
lectin
receptor
tdb
curdlan
shown
neonat
mice
enhanc
protect
influenza
induct
tfh
gc
bone
marrow
highaffin
plasma
cell
suggest
activ
c
type
lectin
receptor
sugarbas
compound
may
specif
bypass
block
innat
immun
pathway
neonat
therebi
boost
neonat
vaccin
respons
increas
inflammatori
cytokin
product
cpgodn
mpla
poli
c
agonist
zymosan
increas
costimulatori
marker
agonist
tlr
agonist
increas
respons
adult
promot
neonat
increas
cell
advax
tfh
cell
improv
tfh
function
advax
curdlan
ddatdb
increas
sustain
ab
respons
advax
curdlan
ddatdb
improv
breadth
function
igg
agonist
b
cell
cell
figur
overcom
function
differ
neonat
immun
system
use
vaccin
adjuv
adjuv
enhanc
immunogen
neonat
vaccin
innat
activ
via
enhanc
multipl
aspect
adapt
immun
adjuv
activ
apc
monocyt
dendrit
cell
increas
cytokin
product
costimulatori
marker
express
improv
prime
cell
follow
activ
antigen
present
cell
differenti
follicular
helper
cell
necessari
germin
center
reaction
assist
b
cell
gener
effect
antibodi
improv
memori
plasma
b
cell
enhanc
antigen
detect
neutral
increas
product
highaffin
antibodi
abbrevi
key
understand
tlr
tolllik
receptor
cpgodn
cpgoligodeoxynucleotid
mpla
monophosphoryl
lipid
ddatdb
dimethyldioctadecyl
ammonium
dda
trehalos
tdb
agonist
contain
imidazoquinolineoilinwat
squalen
emuls
se
advax
delta
inulin
adjuv
delta
inulin
plantbas
polysaccharid
basi
advax
adjuv
inulin
fructan
compris
linear
chain
fructos
unit
connect
glycosid
bond
cap
reduc
end
glucopyranosid
ring
inulin
must
crystal
microparticl
known
delta
inulin
becom
adjuv
activ
solubl
inulin
measur
immunolog
activ
advax
alon
combin
tlr
agonist
prove
effect
enhanc
humor
cellular
immun
adult
anim
broad
rang
pathogen
includ
influenza
japanes
enceph
viru
west
nile
viru
tuberculosi
anthrax
african
hors
sick
hiv
listeria
hbv
amongst
other
review
advax
adjuv
similarli
afford
complet
protect
murin
pup
vaccin
day
age
singledos
inactiv
influenza
vaccin
wherea
influenza
vaccin
alon
provid
protect
advaxformul
vaccin
induc
significantli
higher
level
serum
influenzaspecif
ab
isotyp
plu
fold
increas
frequenc
influenzaspecif
igm
igg
secret
cell
spleen
bone
marrow
pup
immun
advaxformul
vaccin
also
significantli
higher
influenzaspecif
cell
product
togeth
higher
frequenc
influenzaspecif
cell
elispot
secret
advers
effect
observ
advaximmun
pup
even
although
receiv
mg
dose
advax
use
adult
mice
abil
advax
adjuv
enhanc
neonat
influenza
vaccin
protect
effect
rais
mani
question
includ
natur
mechan
wherebi
achiev
effect
notabl
exactli
neonat
influenza
model
shown
agonist
adjuv
activ
provid
protect
oldimmun
pup
manuscript
prepar
neonat
protect
advaxadjuv
influenza
vaccin
depend
function
b
cell
protect
seen
immun
neonat
b
cell
defici
exact
mechan
advax
enhanc
immunogen
influenza
vaccin
anim
model
human
clinic
trial
yet
determin
delta
inulin
activ
classic
inflammatori
innat
immun
receptor
tlr
instead
work
anoth
receptor
nonreceptor
mechan
modul
function
dc
induc
chemotaxi
enhanc
expans
memori
b
cell
murin
tb
studi
addit
advax
agonist
cpg
oligonucleotid
advaxcpg
improv
immunogen
protect
efficaci
novel
tb
vaccin
candid
immun
advaxcpg
result
heighten
releas
chemoattract
rapid
influx
monocyt
neutrophil
site
vaccin
pronounc
earli
prime
cell
human
subject
immun
advaxadjuv
season
influenza
vaccin
increas
serum
neutral
antibodi
titer
increas
frequenc
plasmablast
seen
peripher
blood
day
post
vaccin
plasmablast
sort
sequenc
exhibit
fold
higher
rate
nonsil
mutat
b
cell
receptor
bcr
heavi
chain
complementaritydetermin
region
associ
higher
plasmablast
express
activationinduc
cytidin
deaminas
aicda
major
enzym
control
bcr
affin
matur
provid
mechan
explain
enhanc
neutral
antibodi
respons
seen
subject
receiv
advax
adjuv
studi
ongo
anim
model
determin
advax
adjuv
enhanc
humor
immun
respons
preliminari
result
suggest
depend
enhanc
activ
cell
therebi
hypothes
advax
increas
frequenc
tfh
cell
act
enhanc
antigenspecif
b
cell
activ
bcr
affin
matur
igg
switch
product
high
avid
ab
whether
action
advax
enhanc
activ
cell
might
mediat
interact
one
c
type
lectin
receptor
express
apc
known
howev
advax
noninflammatori
effect
human
pbmc
suggest
act
one
proinflammatori
type
c
type
lectin
receptor
mincl
dcsign
compar
effect
adult
blood
lp
flagellin
poli
c
stimul
weaker
inflammatori
cytokin
product
cord
blood
monocyt
haemophilu
influenza
b
vaccin
adjuv
outer
membran
protein
omp
porin
b
porb
neisseria
meningitidi
agonist
induc
minim
ab
neonat
protect
first
dose
given
month
age
suggest
tlr
signal
alon
may
rel
ineffici
stimul
neonat
vaccin
respons
furthermor
adjuv
induc
respons
adult
paradox
induc
respons
neonat
notabl
advax
combin
tradit
innat
immun
activ
tlr
agonist
enhanc
adjuv
activ
notabl
coformul
cpg
oligonucleotid
advax
enhanc
immunogen
sar
coronaviru
vaccin
also
prevent
vaccineassoci
eosinophil
lung
patholog
problem
exacerb
formul
sar
vaccin
alum
adjuv
henc
interest
see
coformul
advax
cpg
oligonucleotid
perform
neonat
set
major
need
vaccin
use
protect
young
infant
emerg
data
suggest
particular
immun
pathway
includ
c
type
lectin
receptor
respond
sugar
structur
may
particularli
effect
activ
infant
immun
system
may
help
explain
benefici
effect
neonat
vaccin
respons
sugarbas
compound
includ
delta
inulin
advax
curdlan
tdb
henc
addit
research
altern
immun
pathway
induc
sugarbas
compound
might
help
elucid
addit
compound
abl
enhanc
neonat
vaccin
respons
promis
area
investig
develop
neonat
vaccin
pathogen
caus
signific
infant
morbid
mortal
includ
influenza
rsv
million
death
neonat
infant
infecti
diseas
annual
emphas
need
develop
effect
strategi
earlylif
immun
success
bcg
rotaviru
vaccin
given
birth
proofofconcept
effect
safe
neonat
immun
feasibl
framework
allow
discoveri
neonat
agespecif
adjuv
need
compar
respons
variou
immunestimul
cord
adult
blood
may
translat
complex
adjuv
effect
vivo
ultim
answer
come
human
neonat
studi
vaccin
contain
novel
adjuv
assist
progress
need
defin
valid
specif
neonat
biomark
vaccin
adjuv
safeti
efficaci
benefici
effect
neonat
anim
model
sugarbas
adjuv
delta
inulin
curdlan
tdb
neonat
vaccin
respons
highlight
abil
identifi
compound
abl
enhanc
neonat
vaccin
respons
understand
specif
benefit
compound
research
need
differ
immun
signal
pathway
newborn
adult
system
biolog
analysi
host
respons
vaccin
provid
new
insight
adult
immun
respons
vaccin
system
biolog
approach
employ
highthroughput
molecular
cellular
measur
call
omic
analysi
exampl
transcriptom
analys
show
earli
gene
signatur
follow
vaccin
predict
subsequ
measur
immunogen
season
influenza
highdimension
methodolog
could
appli
character
neonat
vaccineinduc
molecular
signatur
correspond
protect
import
formul
vaccin
effect
often
overlook
henc
also
need
research
develop
new
improv
formul
stabl
deliveri
system
improv
neonat
vaccin
immunogen
new
knowledg
help
ration
design
neonat
vaccin
adjuv
reduc
empiric
lessen
risk
fail
vaccin
candid
therebi
expedit
develop
effect
neonat
vaccin
work
support
part
feder
fund
nation
institut
allergi
infecti
diseas
nation
institut
health
depart
health
human
servic
contract
collabor
research
contact
np
clinic
translat
scienc
institut
award
katherin
content
sole
respons
author
necessarili
repres
offici
view
nation
institut
allergi
infecti
diseas
nation
institut
health
sakala
employe
vaxin
pti
ltd
develop
advax
adjuv
academ
affili
flinder
univers
n
petrovski
founder
research
director
vaxin
pti
ltd
academ
affili
flinder
univers
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
peer
review
manuscript
relev
financi
relationship
disclos
